Transcatheter Aortic Valve Implantation (TAVI)

Transcatheter aortic valve implantation (TAVI*) is an investigational (non-FDA approved), less invasive, innovative catheter based therapy to relieve aortic stenosis; it combines the skills of Stanford's cardiologists, cardiovascular surgeons, and cardiovascular anesthesiologists. Outside the U.S., TAVI is assuming a major role in the management of symptomatic patients with severe aortic stenosis, who are unfit to undergo open surgical AVR or who are very high risk for AVR. Stanford has been enrolling in TAVI clinical trials since 2008.